Beyond Biosimilars: Novel Approaches To Treat Wet AMD

Beyond the cost savings of biosimilars, the true evolution in wet AMD treatment is happening by companies developing next-generation therapies that aim to reduce injection burden, introduce novel mechanisms, and potentially alter disease progression.

AMD Acronym Of Age-related Macular Degeneration - Eye
(Shutterstock)

More from Innovation

More from Market Intelligence